Vertex Pharmaceuticals
$506.74Change from previous close: −3.07%Absolute change: −$16.07
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $132.43B
- Enterprise value
- $126.64B
- P/E (trailing 12 months)
- 30.5
- Forward P/E
- 26.0
- PEG
- 2.05
- Price/book
- 6.54
- Price/sales
- 10.5
- EV/EBITDA
- 24.8
- EV/revenue
- 10.1
Profitability and growth
- Gross margin
- 55.0%
- Operating margin
- 38.1%
- Net margin
- 35.0%
- ROE
- 23.5%
- ROA
- 11.9%
- Revenue growth (year over year)
- 12.5%
- Earnings growth (year over year)
- 8.0%
Financial health
- Total cash
- $7.85B
- Total debt
- $1.98B
- Debt/equity
- 0.10
- Current ratio
- 3.19
- Quick ratio
- 2.54
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $571.39
- Median price target
- $577.50
- High price target
- $672.00
- Low price target
- $350.00
- Analysts with a price target
- 28
- Consensus
- Buy
- Forward EPS
- $20.09
- EPS estimate, current year
- $16.17
Shares and trading
- Beta
- 0.32
- Average volume
- 1.23M
- Shares outstanding
- 253.3M
- Float
- 252.69M
- Institutional ownership
- 97.9%
- Insider ownership
- 0.2%
- Short interest (% of float)
- 2.1%
- Short ratio (days)
- 4.72